BRISBANE, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will be presenting at two conferences in November 2016. The details are as follows:
CreditSuisse 25th Annual Healthcare Conference
Monday,
November 7 from 4:30 to 5:00 p.m. (MST)
The Phoenician Hotel,
Scottsdale, Arizona
Webcast Link (archived for 90 days): CreditSuisse
Innoviva Presentation
Stifel 2016 Healthcare Conference
Wednesday, November 16
from 10:15 to 10:55 a.m. (EST)
Lotte New York Palace Hotel, New York
Webcast
Link (archived for 90 days): Stifel
Innoviva Presentation
About Innoviva
Innoviva is focused on bringing compelling
new medicines to patients in areas of unmet need by leveraging its
significant expertise in the development, commercialization and
financial management of bio-pharmaceuticals. Innoviva's portfolio is
anchored by the respiratory assets partnered with Glaxo Group Limited
(GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were
jointly developed by Innoviva and GSK. Under the agreement with GSK,
Innoviva is eligible to receive associated royalty revenues from
RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and
commercialized, VI monotherapy, as well. In addition, Innoviva retains a
15 percent economic interest in future payments made by GSK for
earlier-stage programs partnered with Theravance BioPharma, Inc. For
more information, please visit Innoviva's website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005440/en/
